Primary outcome: Proportion of spontaneous preterm delivery <34 weeks
Proportion of spontaneous preterm births <37 and <28 weeks | Rate of PROM <34 and <37 weeks | Need of tocolysis and corticosteroid | Vaginal side effects | Maternal outcomes such as rate of chorioamnionitis etc.| Newborn outcomes such as birthweight and adverse events (e.g., perinatal death etc.)
Sample size: 254 women were required to show noninferiority of the pessary to progesterone
Noninferiority margin of 4% with a 0.025 one-sided α level (i.e., if the 95% CI upper bound exceeds 4%, the pessary could not be deemed noninferior)
Statistical power of 80%
Assumed dropout rate of 5%
254 patients were enrolled and 246 included in the intention-to-treat analysis
The rate of spontaneous delivery before 34 weeks of gestation was
14% (n=18/127) in the pessary group
14% (n=17/119) in the progesterone group
Risk difference: −0.11% (95% CI −8.85% to 8.62%; P=.99)
Noninferiority was not shown for the pessary
Adverse events were higher in the pessary group compared to progesterone
Incidence of increased vaginal discharge: 87% vs 71% (P=.002)
Discomfort: 27% vs 3% (P<.001)
Cervical pessary was not noninferior to vaginal progesterone
95% CI of the difference exceeded the 4% prespecified non-inferiority margin of 4%
Cervical pessary was associated with increased vaginal discharge and discomfort
Authors recommend vaginal progesterone as the first line treatment as a “first option” but
…the pessary could be considered a similar effective alternative and could be a preferred choice for women reluctant to use daily medication
Please sign up or log in to your ObGFirst to access this Premium Content
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan